The biopharmaceutical industry’s commercial model has been an important part of each company’s success, but the current capabilities and strategies are unlikely to suffice for future complexities and …

AI in Biopharma Artificial intelligence-enabled technologies are transforming the different parts of the biopharma industry value chain, creating new business opportunities. Explore Deloitte's collection of …

Inorganic growth activity in life sciences— have we reached the bottom? Our previous report outlined a steep decline in life sciences deal-making in the first half of 2022 from record levels of mergers and …

Evolving portfolios and value creation The key portfolio decisions that life sciences companies are contemplating today come at a time of contrasts. Big pharma is cash-rich enough to snap up …

Discover unique perspectives on industry-transforming issues. Explore expert ideas around reshaping health care and life sciences to be more human-centered—because better health care starts with …

More than 3/4 of biopharma companies agree that their organizations need new leaders to succeed in the digital age. Many companies are recruiting outside of life sciences for digital expertise. Currently, …

Life sciences companies have access to a vast amount of patient and health care provider (HCP) data to meet regulatory compliance and operational needs. Yet many organizations are underutilizing these …

Government fees for 2025 - Update The reason of this is to inform about the update on the government fees for immigration processes. These fees will be applicable from January 1st, 2025 to December …

www2.deloitte.com

はじめに 中小企業向け保険は過去5年間で最も話題を集めている保険領域の一つである。しかし、注目が高まる一方で、大半の既存保険会社の間で大きな動きは見られていない。中小企業各社は、この …